Welcome to LookChem.com Sign In|Join Free
  • or
Rofecoxib, also known by the brand name Vioxx, is a non-steroidal anti-inflammatory drug (NSAID) that was launched in Mexico for the management of acute pain and the treatment of osteoarthritis (OA) and primary dysmenorrhea. It is a highly selective inhibitor of COX-2, the inducible isoform of cyclooxygenase, which allows it to exhibit potent anti-inflammatory activity without the gastric or renal toxicities associated with non-specific COX-1/2 inhibitors. Rofecoxib was used from 1999 to 2004 for the treatment of osteoarthritis but was withdrawn due to concerns about an increased risk of heart attack and stroke.

162011-90-7

Post Buying Request

162011-90-7 Suppliers

Recommended suppliers

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

162011-90-7 Usage

Uses

Used in Pharmaceutical Industry:
Rofecoxib is used as an anti-inflammatory and analgesic agent for the management of acute pain, osteoarthritis, and primary dysmenorrhea. Its selective COX-2 inhibition allows for reduced gastrointestinal and renal side effects compared to non-selective NSAIDs.
Used in Research and Development:
Rofecoxib is used as an antipsychotic agent in the development of new medications and therapies.
Used in Analytical Chemistry:
Rofecoxib, labeled as Rizatriptan, is intended for use as an internal standard for the quantification of Rizatriptan by gas chromatography (GC) or liquid chromatography (LC) mass spectrometry.
Used in Biochemistry:
Rofecoxib has been utilized in high-performance bioaffinity chromatography for various research applications.

Originator

Merck (US)

Indications

Rofecoxib is approved for the treatment of osteoarthritis, dysmenorrhea, and acute pain. The most common adverse reactions to rofecoxib are mild to moderate GI irritation (diarrhea, nausea, vomiting, dyspepsia, abdominal pain). Lower extremity edema and hypertension occur relatively frequently (about 3.5%). It is not metabolized by CYP2C9, so rofecoxib should not be subject to some of the interactions seen with celecoxib. However, its metabolism is increased by the coadministration of rifampin, which acts as a nonspecific inducer of hepatic metabolism.

Biochem/physiol Actions

Rofecoxib is derived from furanone and has the ability to cross human placenta. Along with anti-inflammatory action, it possesses analgesic and antipyretic properties. Cytosolic hepatic enzymes are responsible for the metabolism of rofecoxib. It is known to cause oligohydramnios and ductus arteriosus constrictions. Rofecoxib inhibits the action of CYP1A2 (cytochrome P450 family 1 subfamily A member 2). It might be associated with aseptic meningitis. Rofecoxib is known to ameliorate the risk of colorectal adenoma, but might contribute to toxicity.

Mechanism of action

Rofecoxib is excreted primarily in the urine (72%) as metabolites. Less than 1% is excreted in the urine as unchanged drug, whereas approximately 14% is excreted in the feces as unchanged drug. Although the metabolism of rofecoxib has not been fully determined, the microsomal cytochrome P450 system appears to play only a minor role—a major difference in the metabolic routes of rofecoxib and celecoxib. The major metabolic route appears to form reduction of the dihydrofuranone ring system by cystolic enzymes to the to cis- and trans- dihydro derivatives. Also isolated is the glucuronide of a hydroxy derivative that results from CYP2C9 oxidative metabolism. None of the isolated metabolites of rofecoxib possess pharmacological activity as COX-1 or COX-2 inhibitors.

Pharmacokinetics

Rofecoxib has been synthesized by a number of synthetic routes that have been summarized elsewhere. It was the second selective COX-2 inhibitor to be marketed. Rofecoxib is well absorbed from the GI tract on oral administration, with peak plasma levels generally being attained within 2 to 3 hours of dosing. Bioavailability averages 93% following administration of a single dose. The area under the plasma concentration–time curve is increased in patients older than 65 years compared to younger adults and is increased slightly in black and Hispanic patients compared with white patients, but the difference is not considered to be clinically significant.

Clinical Use

Rofecoxib was indicated for the relief of the signs and symptoms of osteoarthritis, for the management of acute pain in adults, and for the treatment of primary dysmenorrhea.

References

1) Chan et al. (1999), Rofecoxib [Vioxx, MK-0966; 4-(4′-methylsulfonylphenyl)-3-phenyl-2-(5H)-furanone]: a potent and orally active cyclooxygenase-2 inhibitor. Pharmacological and biochemical profiles; J. Pharmacol. Exp. Ther., 290 551 2) Catalla-Lawson et al. (2013), Effects of specific inhibition of cyclooxygenase-2 on sodium balance, hemodynamics and vasoactive eicosanoids; J. Pharmacol. Exp. Ther., 289 735

Check Digit Verification of cas no

The CAS Registry Mumber 162011-90-7 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,6,2,0,1 and 1 respectively; the second part has 2 digits, 9 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 162011-90:
(8*1)+(7*6)+(6*2)+(5*0)+(4*1)+(3*1)+(2*9)+(1*0)=87
87 % 10 = 7
So 162011-90-7 is a valid CAS Registry Number.
InChI:InChI=1/C17H14O4S/c1-22(19,20)14-9-7-12(8-10-14)15-11-21-17(18)16(15)13-5-3-2-4-6-13/h2-10H,11H2,1H3

162011-90-7 Well-known Company Product Price

  • Brand
  • (Code)Product description
  • CAS number
  • Packaging
  • Price
  • Detail
  • Sigma

  • (SML0613)  Rofecoxib  ≥98% (HPLC)

  • 162011-90-7

  • SML0613-10MG

  • 742.95CNY

  • Detail
  • Sigma

  • (SML0613)  Rofecoxib  ≥98% (HPLC)

  • 162011-90-7

  • SML0613-50MG

  • 3,012.75CNY

  • Detail

162011-90-7SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 17, 2017

Revision Date: Aug 17, 2017

1.Identification

1.1 GHS Product identifier

Product name rofecoxib

1.2 Other means of identification

Product number -
Other names 4-(4-(methylsulfonyl)phenyl)-3-phenylfuran-2(5H)-one

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:162011-90-7 SDS

162011-90-7Synthetic route

4-(4-(methylthio)phenyl)-3-phenylfuran-2(5H)-one
162012-30-8

4-(4-(methylthio)phenyl)-3-phenylfuran-2(5H)-one

rofecoxib
162011-90-7

rofecoxib

Conditions
ConditionsYield
With 3-chloro-benzenecarboperoxoic acid at 0 - 21℃; Oxidation;99%
With Oxone In water; acetone at 0 - 25℃; for 24h; Product distribution / selectivity;95%
With oxone In water; acetone at 0 - 25℃; for 24h;91%
2-(4-methanesulfonylphenyl)-2-oxoethyl 2-(diethoxyphosphoryl)-2-phenylacetate

2-(4-methanesulfonylphenyl)-2-oxoethyl 2-(diethoxyphosphoryl)-2-phenylacetate

rofecoxib
162011-90-7

rofecoxib

Conditions
ConditionsYield
With triethylamine In N,N-dimethyl-formamide at 0 - 30℃; for 2h; Horner-Wadsworth-Emmons Olefination; Inert atmosphere;95%
phenylacetic acid
103-82-2

phenylacetic acid

ethyl bromoacetate
105-36-2

ethyl bromoacetate

rofecoxib
162011-90-7

rofecoxib

Conditions
ConditionsYield
With triethylamine In tetrahydrofuran; water; ethyl acetate94%
2-bromo-1-(4-methanesulfonylphenyl)ethanone
50413-24-6

2-bromo-1-(4-methanesulfonylphenyl)ethanone

2-(diethoxyphosphino)-2-phenylacetic acid
38654-91-0

2-(diethoxyphosphino)-2-phenylacetic acid

rofecoxib
162011-90-7

rofecoxib

Conditions
ConditionsYield
With triethylamine In N,N-dimethyl-formamide at 0 - 30℃; for 2h; Horner-Wadsworth-Emmons Olefination; Inert atmosphere;92%
phenylacetic acid
103-82-2

phenylacetic acid

2-bromo-1-(4-methanesulfonylphenyl)ethanone
50413-24-6

2-bromo-1-(4-methanesulfonylphenyl)ethanone

rofecoxib
162011-90-7

rofecoxib

Conditions
ConditionsYield
Stage #1: phenylacetic acid With sodium hydroxide In DMF (N,N-dimethyl-formamide); water at 4℃; for 1h;
Stage #2: 2-bromo-1-(4-methanesulfonylphenyl)ethanone With diisopropylamine at 45℃; for 3.5h;
78%
Stage #1: phenylacetic acid With sodium hydroxide In N,N-dimethyl-formamide at 20℃; for 1h;
Stage #2: 2-bromo-1-(4-methanesulfonylphenyl)ethanone In N,N-dimethyl-formamide for 1h;
Stage #3: With diisopropylamine In N,N-dimethyl-formamide at 60℃; for 4h;
76%
Stage #1: phenylacetic acid; 2-bromo-1-(4-methanesulfonylphenyl)ethanone With triethylamine In acetonitrile at 20 - 25℃; for 0.333333h;
Stage #2: With 1,8-diazabicyclo[5.4.0]undec-7-ene In acetonitrile at 0℃; for 0.333333h;
58%
3-chloro-4-(4'-methylsulfonylphenyl)-5H-furan-2-one
487047-31-4

3-chloro-4-(4'-methylsulfonylphenyl)-5H-furan-2-one

phenylboronic acid
98-80-6

phenylboronic acid

rofecoxib
162011-90-7

rofecoxib

Conditions
ConditionsYield
With N-benzyl-N,N,N-triethylammonium chloride; cesium fluoride; bis-triphenylphosphine-palladium(II) chloride In water; toluene for 7h; Suzuki cross-coupling; Heating;74%
With cesium fluoride; bis-triphenylphosphine-palladium(II) chloride; N-benzyl-N,N,N-triethylammonium chloride In water; toluene for 7h; Product distribution / selectivity; Suzuki Coupling; Heating / reflux;74%
C16H11IO2

C16H11IO2

methyl p-toluene sulfonate
80-48-8

methyl p-toluene sulfonate

rofecoxib
162011-90-7

rofecoxib

Conditions
ConditionsYield
With 1,1'-bis-(diphenylphosphino)ferrocene; sodium metabisulfite; (1,1'-bis(diphenylphosphino)ferrocene)palladium(II) dichloride; tin; potassium hydrogenphosphate trihydrate; tetrabutylammomium bromide In dimethyl sulfoxide at 100℃; for 10h; Inert atmosphere; Schlenk technique;59%
With 1,1'-bis-(diphenylphosphino)ferrocene; sodium metabisulfite; (1,1'-bis(diphenylphosphino)ferrocene)palladium(II) dichloride; tin; potassium hydrogenphosphate trihydrate; tetrabutylammomium bromide In dimethyl sulfoxide at 100℃; for 10h; Inert atmosphere;59%
C12H10O4

C12H10O4

4-methanesulphonylphenylboronic acid
149104-88-1

4-methanesulphonylphenylboronic acid

rofecoxib
162011-90-7

rofecoxib

Conditions
ConditionsYield
With palladium(0)bis(tricyclohexylphosphine) In water; toluene at 100℃; for 24h; Inert atmosphere; Glovebox;45%
4-(methylsulfonyl)benzoylmethyl phenylacetate
201737-94-2

4-(methylsulfonyl)benzoylmethyl phenylacetate

rofecoxib
162011-90-7

rofecoxib

Conditions
ConditionsYield
With 1,8-diazabicyclo[5.4.0]undec-7-ene In acetonitrile at 0℃; for 0.5h;
With diisopropylamine In DMF (N,N-dimethyl-formamide) at 45℃; for 4.25h;
With 1,8-diazabicyclo[5.4.0]undec-7-ene In acetonitrile Horner-Wadsworth-Emmons Olefination;
phenylacetic acid
103-82-2

phenylacetic acid

Fmoc-L-Val-(p-methylbenzhydrylamine resin)

Fmoc-L-Val-(p-methylbenzhydrylamine resin)

rofecoxib
162011-90-7

rofecoxib

Conditions
ConditionsYield
Multi-step reaction with 2 steps
1: Et3N / acetonitrile / 0.5 h / 25 °C
2: DBU / acetonitrile / 0.5 h / 0 °C
View Scheme
2-bromo-1-(4-methanesulfonylphenyl)ethanone
50413-24-6

2-bromo-1-(4-methanesulfonylphenyl)ethanone

rofecoxib
162011-90-7

rofecoxib

Conditions
ConditionsYield
Multi-step reaction with 2 steps
1: Et3N / acetonitrile / 0.5 h / 25 °C
2: DBU / acetonitrile / 0.5 h / 0 °C
View Scheme
(4-thiomethoxyphenyl)boronic acid
98546-51-1

(4-thiomethoxyphenyl)boronic acid

rofecoxib
162011-90-7

rofecoxib

Conditions
ConditionsYield
Multi-step reaction with 3 steps
1: cesium fluoride; BnEt3NCl / PdCl2(PPh3)2 / toluene; H2O / 72 h / 20 - 25 °C
2: 85 percent / Oxone(R) / acetone; H2O / 0 - 25 °C
3: 74 percent / cesium fluoride; BnEt3NCl / PdCl2(PPh3)2 / toluene; H2O / 7 h / Heating
View Scheme
Multi-step reaction with 3 steps
1: cesium fluoride; BnEt3NCl / PdCl2(PPh3)2 / toluene; H2O / 72 h / 20 - 25 °C
2: cesium fluoride; BnEt3NCl / PdCl2(PPh3)2 / toluene; H2O / 20 - 25 °C
3: 91 percent / Oxone(R) / acetone; H2O / 24 h / 0 - 25 °C
View Scheme
3-bromo-4-(4'-methylthiophenyl)-5H-furan-2-one
329328-49-6

3-bromo-4-(4'-methylthiophenyl)-5H-furan-2-one

rofecoxib
162011-90-7

rofecoxib

Conditions
ConditionsYield
Multi-step reaction with 2 steps
1: 95 percent / cesium fluoride; BnEt3NCl / PdCl2(PPh3)2 / toluene; H2O / Heating
2: 91 percent / Oxone(R) / acetone; H2O / 24 h / 0 - 25 °C
View Scheme
Multi-step reaction with 2 steps
1: 68 percent / AsPh3; CuI / Pd2(dba)3 / 1-methyl-pyrrolidin-2-one / 63 h / 80 °C
2: 80 percent / oxone; aq. Bu4NBr / CH2Cl2 / 46.5 h / 20 °C
View Scheme
3-chloro-4-(4'-methylthiophenyl)-5H-furan-2-one
487047-30-3

3-chloro-4-(4'-methylthiophenyl)-5H-furan-2-one

rofecoxib
162011-90-7

rofecoxib

Conditions
ConditionsYield
Multi-step reaction with 2 steps
1: 85 percent / Oxone(R) / acetone; H2O / 0 - 25 °C
2: 74 percent / cesium fluoride; BnEt3NCl / PdCl2(PPh3)2 / toluene; H2O / 7 h / Heating
View Scheme
Multi-step reaction with 2 steps
1: cesium fluoride; BnEt3NCl / PdCl2(PPh3)2 / toluene; H2O / 20 - 25 °C
2: 91 percent / Oxone(R) / acetone; H2O / 24 h / 0 - 25 °C
View Scheme
4-(Methylthio)acetophenone
1778-09-2

4-(Methylthio)acetophenone

rofecoxib
162011-90-7

rofecoxib

Conditions
ConditionsYield
Multi-step reaction with 3 steps
1.1: 100 percent / MMPP / methanol; CH2Cl2 / 3 h / 20 °C
2.1: 86 percent / Br2; AlCl3 / CHCl3 / -5 °C
3.1: Et3N / acetonitrile / 0.33 h / 25 °C
3.2: 54 percent / DBU / acetonitrile / 0.33 h / 0 °C
View Scheme
Multi-step reaction with 3 steps
1.1: acetic acid; dihydrogen peroxide; sulfuric acid / 2 h / 0 - 70 °C
2.1: acetic acid; hydrogen bromide / 0.08 h / 20 °C
2.2: 2.5 h / 25 - 58 °C
3.1: sodium hydroxide / N,N-dimethyl-formamide / 1 h / 20 °C
3.2: 1 h
3.3: 4 h / 60 °C
View Scheme
Multi-step reaction with 4 steps
1: tetra-N-butylammonium tribromide / methanol; dichloromethane
2: sodium hydroxide / water; dichloromethane
3: diisopropylamine / dimethyl sulfoxide
4: dihydrogen peroxide; sodium tungstate (VI) dihydrate / water; acetonitrile / 5.5 h / 65 - 70 °C
View Scheme
methyl-phenyl-thioether
100-68-5

methyl-phenyl-thioether

rofecoxib
162011-90-7

rofecoxib

Conditions
ConditionsYield
Multi-step reaction with 4 steps
1.1: 82 percent / AlCl3 / CHCl3 / 1.5 h / 5 °C
2.1: 100 percent / MMPP / methanol; CH2Cl2 / 3 h / 20 °C
3.1: 86 percent / Br2; AlCl3 / CHCl3 / -5 °C
4.1: Et3N / acetonitrile / 0.33 h / 25 °C
4.2: 54 percent / DBU / acetonitrile / 0.33 h / 0 °C
View Scheme
Multi-step reaction with 4 steps
1.1: aluminum (III) chloride / chloroform / 1.5 h / -5 - 5 °C / Cooling with ice
2.1: acetic acid; dihydrogen peroxide; sulfuric acid / 2 h / 0 - 70 °C
3.1: acetic acid; hydrogen bromide / 0.08 h / 20 °C
3.2: 2.5 h / 25 - 58 °C
4.1: sodium hydroxide / N,N-dimethyl-formamide / 1 h / 20 °C
4.2: 1 h
4.3: 4 h / 60 °C
View Scheme
4-(methanesulfonyl)acetophenone
10297-73-1

4-(methanesulfonyl)acetophenone

rofecoxib
162011-90-7

rofecoxib

Conditions
ConditionsYield
Multi-step reaction with 2 steps
1.1: 86 percent / Br2; AlCl3 / CHCl3 / -5 °C
2.1: Et3N / acetonitrile / 0.33 h / 25 °C
2.2: 54 percent / DBU / acetonitrile / 0.33 h / 0 °C
View Scheme
Multi-step reaction with 2 steps
1.1: acetic acid; hydrogen bromide / 0.08 h / 20 °C
1.2: 2.5 h / 25 - 58 °C
2.1: sodium hydroxide / N,N-dimethyl-formamide / 1 h / 20 °C
2.2: 1 h
2.3: 4 h / 60 °C
View Scheme
tributylphenylstannane
960-16-7

tributylphenylstannane

rofecoxib
162011-90-7

rofecoxib

Conditions
ConditionsYield
Multi-step reaction with 2 steps
1: 68 percent / AsPh3; CuI / Pd2(dba)3 / 1-methyl-pyrrolidin-2-one / 63 h / 80 °C
2: 80 percent / oxone; aq. Bu4NBr / CH2Cl2 / 46.5 h / 20 °C
View Scheme
3-Phenyl-2-propyn-1-ol
1504-58-1

3-Phenyl-2-propyn-1-ol

rofecoxib
162011-90-7

rofecoxib

Conditions
ConditionsYield
Multi-step reaction with 3 steps
1: tetrahydrofuran; cyclohexane / 19 h / 80 °C
3: 99 percent / m-CPBA / 0 - 21 °C
View Scheme
(4-methylsulfanylphenyl)magnesium chloride

(4-methylsulfanylphenyl)magnesium chloride

rofecoxib
162011-90-7

rofecoxib

Conditions
ConditionsYield
Multi-step reaction with 3 steps
1: tetrahydrofuran; cyclohexane / 19 h / 80 °C
3: 99 percent / m-CPBA / 0 - 21 °C
View Scheme
C16H14MgOS

C16H14MgOS

rofecoxib
162011-90-7

rofecoxib

Conditions
ConditionsYield
Multi-step reaction with 2 steps
2: 99 percent / m-CPBA / 0 - 21 °C
View Scheme
phenylacetic acid
103-82-2

phenylacetic acid

water
7732-18-5

water

triethylamine
121-44-8

triethylamine

2-bromo-1-(4-methanesulfonylphenyl)ethanone
50413-24-6

2-bromo-1-(4-methanesulfonylphenyl)ethanone

rofecoxib
162011-90-7

rofecoxib

Conditions
ConditionsYield
With 1,8-diazabicyclo[5.4.0]undec-7-ene In acetonitrile
With 1,8-diazabicyclo[5.4.0]undec-7-ene In acetonitrile
With 1,8-diazabicyclo[5.4.0]undec-7-ene In acetonitrile
phenylacetic acid
103-82-2

phenylacetic acid

triethylamine
121-44-8

triethylamine

2-bromo-1-(4-methanesulfonylphenyl)ethanone
50413-24-6

2-bromo-1-(4-methanesulfonylphenyl)ethanone

rofecoxib
162011-90-7

rofecoxib

Conditions
ConditionsYield
With 1,8-diazabicyclo[5.4.0]undec-7-ene In water; acetonitrile
2-bromo-1-(4-methylsulfanyl-phenyl)-ethanone
42445-46-5

2-bromo-1-(4-methylsulfanyl-phenyl)-ethanone

rofecoxib
162011-90-7

rofecoxib

Conditions
ConditionsYield
Multi-step reaction with 3 steps
1: N-ethyl-N,N-diisopropylamine / acetonitrile / 20 °C
2: sodium hydride / dimethyl sulfoxide / 1 h / 0 °C
3: uranyl(VI) acetate dihydrate; oxygen / water; acetonitrile; o-xylene / 20 °C / 760.05 Torr / Schlenk technique; Irradiation
View Scheme
Multi-step reaction with 3 steps
1: sodium hydroxide / water; dichloromethane
2: diisopropylamine / dimethyl sulfoxide
3: dihydrogen peroxide; sodium tungstate (VI) dihydrate / water; acetonitrile / 5.5 h / 65 - 70 °C
View Scheme
phenylacetic acid
103-82-2

phenylacetic acid

rofecoxib
162011-90-7

rofecoxib

Conditions
ConditionsYield
Multi-step reaction with 3 steps
1: N-ethyl-N,N-diisopropylamine / acetonitrile / 20 °C
2: sodium hydride / dimethyl sulfoxide / 1 h / 0 °C
3: uranyl(VI) acetate dihydrate; oxygen / water; acetonitrile; o-xylene / 20 °C / 760.05 Torr / Schlenk technique; Irradiation
View Scheme
2-(4-(methylthio)phenyl)-2-oxoethyl 2-phenylacetate

2-(4-(methylthio)phenyl)-2-oxoethyl 2-phenylacetate

rofecoxib
162011-90-7

rofecoxib

Conditions
ConditionsYield
Multi-step reaction with 2 steps
1: sodium hydride / dimethyl sulfoxide / 1 h / 0 °C
2: uranyl(VI) acetate dihydrate; oxygen / water; acetonitrile; o-xylene / 20 °C / 760.05 Torr / Schlenk technique; Irradiation
View Scheme
Multi-step reaction with 2 steps
1: diisopropylamine / dimethyl sulfoxide
2: dihydrogen peroxide; sodium tungstate (VI) dihydrate / water; acetonitrile / 5.5 h / 65 - 70 °C
View Scheme
3-phenyltetronic acid
23782-85-6

3-phenyltetronic acid

rofecoxib
162011-90-7

rofecoxib

Conditions
ConditionsYield
Multi-step reaction with 2 steps
1: N-ethyl-N,N-diisopropylamine / toluene / 17 h
2: palladium(0)bis(tricyclohexylphosphine) / toluene; water / 24 h / 100 °C / Inert atmosphere; Glovebox
View Scheme
rofecoxib
162011-90-7

rofecoxib

(3S,4R)-4-(4-Methanesulfonyl-phenyl)-3-phenyl-dihydro-furan-2-one

(3S,4R)-4-(4-Methanesulfonyl-phenyl)-3-phenyl-dihydro-furan-2-one

Conditions
ConditionsYield
With hydrogen; palladium on activated charcoal In ethanol; ethyl acetate under 2585.74 Torr;100%
4-dimethylamino-benzaldehyde
100-10-7

4-dimethylamino-benzaldehyde

rofecoxib
162011-90-7

rofecoxib

(5Z)-5-(4-(dimethylamino)benzylidene)-4-(4-(methylsulfonyl)phenyl)-3-phenylfuran-2(5H)-one
1448458-89-6

(5Z)-5-(4-(dimethylamino)benzylidene)-4-(4-(methylsulfonyl)phenyl)-3-phenylfuran-2(5H)-one

Conditions
ConditionsYield
With sodium carbonate In methanol at 65℃; stereoselective reaction;95%
rofecoxib
162011-90-7

rofecoxib

5-Hydroxyrofecoxib
185147-17-5

5-Hydroxyrofecoxib

Conditions
ConditionsYield
With oxygen; pyrographite In ethyl acetate92%
With hepatic enzymes; oxygen; NADPH
Multi-step reaction with 2 steps
1: NBS
2: aq. AcOH / tetrahydrofuran
View Scheme
With sodium sulfite In dimethyl sulfoxide at 60℃; for 6h; Temperature; Time;
ortho-anisaldehyde
135-02-4

ortho-anisaldehyde

rofecoxib
162011-90-7

rofecoxib

(5Z)-5-(2-methoxybenzylidene)-4-(4-(methylsulfonyl)phenyl)-3-phenylfuran-2(5H)-one
1448458-79-4

(5Z)-5-(2-methoxybenzylidene)-4-(4-(methylsulfonyl)phenyl)-3-phenylfuran-2(5H)-one

Conditions
ConditionsYield
With sodium carbonate In methanol at 65℃; stereoselective reaction;92%
piperonal
120-57-0

piperonal

rofecoxib
162011-90-7

rofecoxib

(5Z)-5-((benzo[d][1,3]dioxol-5-yl)methylene)-4-(4-(methylsulfonyl)phenyl)-3-phenylfuran-2(5H)-one
1448458-91-0

(5Z)-5-((benzo[d][1,3]dioxol-5-yl)methylene)-4-(4-(methylsulfonyl)phenyl)-3-phenylfuran-2(5H)-one

Conditions
ConditionsYield
With sodium carbonate In methanol at 65℃; stereoselective reaction;91%
benzaldehyde
100-52-7

benzaldehyde

rofecoxib
162011-90-7

rofecoxib

(5Z)-5-(benzylidene)-4-(4-(methylsulfonyl)phenyl)-3-phenylfuran-2(5H)-one
1448458-77-2

(5Z)-5-(benzylidene)-4-(4-(methylsulfonyl)phenyl)-3-phenylfuran-2(5H)-one

Conditions
ConditionsYield
With sodium carbonate In methanol at 65℃; stereoselective reaction;90%
3-nitro-benzaldehyde
99-61-6

3-nitro-benzaldehyde

rofecoxib
162011-90-7

rofecoxib

(5Z)-5-(3-nitrobenzylidene)-4-(4-(methylsulfonyl)phenyl)-3-phenylfuran-2(5H)-one
1448458-78-3

(5Z)-5-(3-nitrobenzylidene)-4-(4-(methylsulfonyl)phenyl)-3-phenylfuran-2(5H)-one

Conditions
ConditionsYield
With sodium carbonate In methanol at 65℃; stereoselective reaction;90%
3,4,5-trimethoxy-benzaldehyde
86-81-7

3,4,5-trimethoxy-benzaldehyde

rofecoxib
162011-90-7

rofecoxib

(5Z)-5-(3,4,5-trimethoxybenzylidene)-4-(4-(methylsulfonyl)phenyl)-3-phenylfuran-2(5H)-one
1448458-80-7

(5Z)-5-(3,4,5-trimethoxybenzylidene)-4-(4-(methylsulfonyl)phenyl)-3-phenylfuran-2(5H)-one

Conditions
ConditionsYield
With sodium carbonate In methanol at 65℃; stereoselective reaction;90%
vanillin
121-33-5

vanillin

rofecoxib
162011-90-7

rofecoxib

(5Z)-5-(4-hydroxy-3-methoxybenzylidene)-4-(4-(methylsulfonyl)phenyl)-3-phenylfuran-2(5H)-one
1448458-82-9

(5Z)-5-(4-hydroxy-3-methoxybenzylidene)-4-(4-(methylsulfonyl)phenyl)-3-phenylfuran-2(5H)-one

Conditions
ConditionsYield
With sodium carbonate In methanol at 65℃; stereoselective reaction;90%
4-methoxy-benzaldehyde
123-11-5

4-methoxy-benzaldehyde

rofecoxib
162011-90-7

rofecoxib

(5Z)-5-(4-methoxybenzylidene)-4-(4-(methylsulfonyl)phenyl)-3-phenylfuran-2(5H)-one
1448458-92-1

(5Z)-5-(4-methoxybenzylidene)-4-(4-(methylsulfonyl)phenyl)-3-phenylfuran-2(5H)-one

Conditions
ConditionsYield
With sodium carbonate In methanol at 65℃; stereoselective reaction;90%
4-cyanobenzaldehyde
105-07-7

4-cyanobenzaldehyde

rofecoxib
162011-90-7

rofecoxib

(5Z)-5-(4-cyanobenzylidene)-4-(4-(methylsulfonyl)phenyl)-3-phenylfuran-2(5H)-one

(5Z)-5-(4-cyanobenzylidene)-4-(4-(methylsulfonyl)phenyl)-3-phenylfuran-2(5H)-one

Conditions
ConditionsYield
With piperidine In methanol at 20℃; for 12h; Darkness;89%
furfural
98-01-1

furfural

rofecoxib
162011-90-7

rofecoxib

(5Z)-5-((furan-2-yl)methylene)-4-(4-(methylsulfonyl)phenyl)-3-phenylfuran-2(5H)-one
1448458-81-8

(5Z)-5-((furan-2-yl)methylene)-4-(4-(methylsulfonyl)phenyl)-3-phenylfuran-2(5H)-one

Conditions
ConditionsYield
With sodium carbonate In methanol at 65℃; stereoselective reaction;88%
1-naphthaldehyde
66-77-3

1-naphthaldehyde

rofecoxib
162011-90-7

rofecoxib

(5Z)-4-(4-(methylsulfonyl)phenyl)-5-((naphthalen-1-yl)methylene)-3-phenylfuran-2(5H)-one
1448458-93-2

(5Z)-4-(4-(methylsulfonyl)phenyl)-5-((naphthalen-1-yl)methylene)-3-phenylfuran-2(5H)-one

Conditions
ConditionsYield
With sodium carbonate In methanol at 65℃; stereoselective reaction;88%
4-bromo-benzaldehyde
1122-91-4

4-bromo-benzaldehyde

rofecoxib
162011-90-7

rofecoxib

(5Z)-5-(4-fluorobenzylidene)-4-(4-(methylsulfonyl)phenyl)-3-phenylfuran-2(5H)-one
1448458-84-1

(5Z)-5-(4-fluorobenzylidene)-4-(4-(methylsulfonyl)phenyl)-3-phenylfuran-2(5H)-one

Conditions
ConditionsYield
With sodium carbonate In methanol at 65℃; stereoselective reaction;86%
4-chlorobenzaldehyde
104-88-1

4-chlorobenzaldehyde

rofecoxib
162011-90-7

rofecoxib

(5Z)-5-(4-chlorobenzylidene)-4-(4-(methylsulfonyl)phenyl)-3-phenylfuran-2(5H)-one
1448458-85-2

(5Z)-5-(4-chlorobenzylidene)-4-(4-(methylsulfonyl)phenyl)-3-phenylfuran-2(5H)-one

Conditions
ConditionsYield
With sodium carbonate In methanol at 65℃; stereoselective reaction;85%
4-hydroxy-benzaldehyde
123-08-0

4-hydroxy-benzaldehyde

rofecoxib
162011-90-7

rofecoxib

(5Z)-5-(4-hydroxybenzylidene)-4-(4-(methylsulfonyl)phenyl)-3-phenylfuran-2(5H)-one
1448458-83-0

(5Z)-5-(4-hydroxybenzylidene)-4-(4-(methylsulfonyl)phenyl)-3-phenylfuran-2(5H)-one

Conditions
ConditionsYield
With sodium carbonate In methanol at 65℃; stereoselective reaction;84%
rofecoxib
162011-90-7

rofecoxib

(E/Z)-3,7-dimethyl-2,6-octadienal
5392-40-5

(E/Z)-3,7-dimethyl-2,6-octadienal

(5Z)-5-((Z/E)-3,7-dimethylocta-2,6-dienylidene)-4-(4-(methylsulfonyl)phenyl)-3-phenylfuran-2(5H)-one
1448459-29-7

(5Z)-5-((Z/E)-3,7-dimethylocta-2,6-dienylidene)-4-(4-(methylsulfonyl)phenyl)-3-phenylfuran-2(5H)-one

Conditions
ConditionsYield
With sodium carbonate In methanol at 65℃; stereoselective reaction;80%
acetone
67-64-1

acetone

rofecoxib
162011-90-7

rofecoxib

4-(4-(methylsulfonyl)phenyl)-3-phenyl-5-(propan-2-ylidene)furan-2(5H)-one
1448458-94-3

4-(4-(methylsulfonyl)phenyl)-3-phenyl-5-(propan-2-ylidene)furan-2(5H)-one

Conditions
ConditionsYield
With sodium carbonate In methanol at 65℃; stereoselective reaction;70%
acetic acid methyl ester
79-20-9

acetic acid methyl ester

rofecoxib
162011-90-7

rofecoxib

5-methoxy-5-methyl-4-(4-(methylsulfonyl)phenyl)-3-phenylfuran-2(5H)-one
185147-25-5

5-methoxy-5-methyl-4-(4-(methylsulfonyl)phenyl)-3-phenylfuran-2(5H)-one

Conditions
ConditionsYield
With sodium carbonate In methanol at 65℃; stereoselective reaction;63%
rofecoxib
162011-90-7

rofecoxib

(2Z)-2-[4-(methylsulfonyl)phenyl]-3-phenylbut-2-ene-1,4-diol
179174-76-6

(2Z)-2-[4-(methylsulfonyl)phenyl]-3-phenylbut-2-ene-1,4-diol

Conditions
ConditionsYield
With diisobutylaluminium hydride In tetrahydrofuran at 0 - 25℃;
Stage #1: rofecoxib With diisobutylaluminium hydride In dichloromethane at -78 - 20℃;
Stage #2: With sodium hydroxide; water In dichloromethane at -78 - 20℃;
With sodium hydroxide; diisobutylaluminium hydride In dichloromethane
Stage #1: rofecoxib With diisobutylaluminium hydride In dichloromethane at -78 - 20℃;
Stage #2: With sodium hydroxide In dichloromethane; water at -78 - 20℃;
rofecoxib
162011-90-7

rofecoxib

(+/-)-5-bromo-4-[4-(methylsulfonyl)phenyl]-3-phenylfuran-2(5H)-one
691005-66-0

(+/-)-5-bromo-4-[4-(methylsulfonyl)phenyl]-3-phenylfuran-2(5H)-one

Conditions
ConditionsYield
With N-Bromosuccinimide
With N-Bromosuccinimide; dibenzoyl peroxide In chloroform for 24h; Heating / reflux;

162011-90-7Relevant academic research and scientific papers

Electrochemical oxygenation of sulfides with molecular oxygen or water: Switchable preparation of sulfoxides and sulfones

Li, Jin-Heng,Li, Yang,Sun, Qing,Xue, Qi,Zhang, Ting-Ting

supporting information, p. 10314 - 10318 (2021/12/17)

A practical and eco-friendly method for the controllable aerobic oxygenation of sulfides by electrochemical catalysis was developed. The switchable preparation of sulfoxides and sulfones was effectively controlled by reaction time, in which both molecular oxygen and water can be used as the oxygen source under catalyst and external oxidant-free conditions. The electrochemical protocol features a broad substrate scope and excellent site selectivity and is successfully applied to the modification of some sulfide-containing pharmaceuticals and their derivatives. This journal is

Palladium-Catalyzed Cross-Coupling of Alkenyl Carboxylates

Becica, Joseph,Heath, Oliver R. J.,Leitch, David C.,Zheng, Cameron H. M.

, p. 17277 - 17281 (2020/07/31)

Carboxylate esters have many desirable features as electrophiles for catalytic cross-coupling: they are easy to access, robust during multistep synthesis, and mass-efficient in coupling reactions. Alkenyl carboxylates, a class of readily prepared non-aromatic electrophiles, remain difficult to functionalize through cross-coupling. We demonstrate that Pd catalysis is effective for coupling electron-deficient alkenyl carboxylates with arylboronic acids in the absence of base or oxidants. Furthermore, these reactions can proceed by two distinct mechanisms for C?O bond activation. A Pd0/II catalytic cycle is viable when using a Pd0 precatalyst, with turnover-limiting C?O oxidative addition; however, an alternative pathway that involves alkene carbopalladation and β-carboxyl elimination is proposed for PdII precatalysts. This work provides a clear path toward engaging myriad oxygen-based electrophiles in Pd-catalyzed cross-coupling.

Selective oxidation of (hetero)sulfides with molecular oxygen under clean conditions

Liu, Kai-Jian,Deng, Ji-Hui,Yang, Jie,Gong, Shao-Feng,Lin, Ying-Wu,He, Jun-Yi,Cao, Zhong,He, Wei-Min

supporting information, p. 433 - 438 (2020/02/13)

The development of eco-friendly and switchable catalytic systems for the conversion of a sole raw-material into distinct high-value products is a particularly attractive concept and a daunting synthetic challenge. In the present work, the first example of efficient and selective oxidation of sulfides to sulfones and sulfoxides using molecular oxygen under clean conditions was established.

Oxidation of aromatic sulfides with molecular oxygen: Controllable synthesis of sulfoxides or sulfones

Tang, Lili,Du, Kejie,Yu, Bing,He, Liangnian

, p. 2991 - 2992 (2020/03/24)

The recent development of selective oxidation of aromatic sulfides with molecular oxygen was highlighted. The sulfoxides and sulfones could be obtained by simply switching the reaction media, i.e., bis(2-butoxyethyl)ether (BBE) or poly(ethylene glycol)dimethyl ether (PEGDME). The application of the high-boiling-point polyether as an initiator and green media can eliminate the need of large quantities of additives and volatile solvents. This strategy represents an economic and eco-friendly method that could find potential applications.

PURIFIED FORMS OF ROFECOXIB, METHODS OF MANUFACTURE AND USE

-

Paragraph 0069; 0081; 0334-0340; 0365-0387; 0394-0400, (2020/06/10)

The subject matter disclosed herein relates to rofecoxib, also known as TRM-201 or RXB-201, its method of manufacture, and use. In certain aspects, the highly pure or substantially pure rofecoxib as provided herein has a favorable purity profile and is the active ingredient in a pharmaceutical composition that is administered to treat or prevent a number of conditions, including pain associated with a condition caused by a bleeding disorder.

Multicomponent Reductive Cross-Coupling of an Inorganic Sulfur Dioxide Surrogate: Straightforward Construction of Diversely Functionalized Sulfones

Meng, Yingying,Wang, Ming,Jiang, Xuefeng

supporting information, p. 1346 - 1353 (2019/12/11)

Conventionally, sulfones are prepared by oxidation of sulfides with strong oxidants. Now, a multicomponent reductive cross-coupling involving an inorganic salt (sodium metabisulfite) for the straightforward construction of sulfones is disclosed. Both intramolecular and intermolecular reductive cross-couplings were comprehensively explored, and diverse sulfones were accessible from the corresponding alkyl and aryl halides. Intramolecular cyclic sulfones were systematically obtained from five- to twelve-membered rings. Naturally occurring aliphatic systems, such as steroids, saccharides, and amino acids, were highly compatible with the SO2-insertion reductive cross-coupling. Four clinically applied drug molecules, which include multiple heteroatoms and functional groups with active hydrogens, were successfully prepared via a late-stage SO2 insertion. Mechanistic studies show that alkyl radicals and sulfonyl radicals were both involved as intermediates in this transformation.

Selective Late-Stage Oxygenation of Sulfides with Ground-State Oxygen by Uranyl Photocatalysis

Li, Yiming,Rizvi, S. Aal-e-Ali,Hu, Deqing,Sun, Danwen,Gao, Anhui,Zhou, Yubo,Li, Jia,Jiang, Xuefeng

supporting information, p. 13499 - 13506 (2019/08/21)

Oxygenation is a fundamental transformation in synthesis. Herein, we describe the selective late-stage oxygenation of sulfur-containing complex molecules with ground-state oxygen under ambient conditions. The high oxidation potential of the active uranyl cation (UO22+) enabled the efficient synthesis of sulfones. The ligand-to-metal charge transfer process (LMCT) from O 2p to U 5f within the O=U=O group, which generates a UV center and an oxygen radical, is assumed to be affected by the solvent and additives, and can be tuned to promote selective sulfoxidation. This tunable strategy enabled the batch synthesis of 32 pharmaceuticals and analogues by late-stage oxygenation in an atom- and step-efficient manner.

Sulfoxide and sulfone compounds, as well as selective synthesis method and application thereof

-

Paragraph 0049-0052; 0174-0177, (2019/12/02)

The invention discloses a method for selectively synthesizing a sulfoxide compound shown as a formula (II) and a sulfone compound shown as a formula (III). In a reaction solvent, thioether (I) is usedas a reaction raw material and oxygen as an oxidation reagent, under the catalytic action of visible light and a photosensitive reagent; under the assistance of an additive, when a large-polarity proton-containing additive such as an acid and an alcohol or a solvent or an additive with excellent electron donating ability is used, a sulfoxide compound (II) is selectively generated; and when a small-polarity aprotic additive or a solvent is used, a sulfone compound (III) is selectively generated. The synthesis method has the advantages of easily available and cheap raw materials, simple reaction operation, mild reaction conditions, high yield and excellent functional group tolerance. According to the invention, synthesis and modification of some medicines are realized, and an efficient method for selectively constructing sulfoxide and sulfone compounds is provided for medicinal chemistry research.

Aryl alkyl sulfone compound and reducing coupling method for constructing sulfone compounds

-

Paragraph 0377-0381, (2019/12/25)

The invention discloses an aryl alkyl sulfone compound shown as a formula (1) and a synthetic method thereof. The aryl alkyl sulfone compound is prepared by taking an aromatic iodide, an inorganic sulfur reagent and an alkyl bromide as reaction raw materials to carry out reacting in a solvent under action of alkali, a catalyst, a ligand, a reducing agent and an additive. According to the invention, an inorganic sulfur reagent is used as a sulfur source to construct the aryl alkyl sulfone compound in one step under catalysis and reduction conditions, so that the defect in synthesizing the arylalkyl sulfone compound by conventional oxidation of thioether is avoided. The aryl alkyl sulfone compound developed by the invention can be used for synthesizing aryl alkyl sulfone medicines.

Stereoselective synthesis and anti-proliferative effects on prostate cancer evaluation of 5-substituted-3,4-diphenylfuran-2-ones

Liu, Gai-Zhi,Xu, Hai-Wei,Wang, Peng,Lin, Zong-Tao,Duan, Ying-Chao,Zheng, Jia-Xin,Liu, Hong-Min

, p. 323 - 336 (2013/10/01)

Series of 5-substituted-3,4-diphenylfuran-2-ones were stereoselectively prepared. Their potential anti-proliferative effects on prostate cancer and some of their cyclooxygenases (COXs) inhibitory activities were evaluated. Structure-activity relationship (SAR) data, acquired by substituent modification at the para-position and ortho-position of the C-3 phenyl ring and 5-substituted modification of the central furanone, showed that 3-(2-chloro-phenyl)-4-(4-methanesulfonyl-phenyl)-5-(1-methoxy-ethyl) -5H-furan-2-one (13p) was the most potent compound and could effectively reduce the proliferation of prostate cancer cells (PC3 cell IC50 = 20 μM; PC3 PCDNA cell IC50 = 5 μM; PC3 SKP2 cell IC50 = 5 μM; DU145 cell IC50 = 25 μM). The cell cycle analysis for 13p in DU145 indicated that 13p may induce G1 phase arrest.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1 Customer Service

What can I do for you?
Get Best Price

Get Best Price for 162011-90-7